

# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

<b>1: Authorisation Number</b>	UK MIA(IMP) 40211
<b>2: Name of authorisation holder</b>	SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED
<b>3: Address(es) of manufacturing site(s)</b>	SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM
<b>4: Legally registered address of authorisation holder</b>	SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, UNIT 10, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING, FK9 4NF, UNITED KINGDOM
<b>5: Scope of authorisation and dosage forms</b>	ANNEX 1 and/ or ANNEX 2
<b>6: Legal Basis of authorisation</b>	Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]
<b>7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation</b>	Confidential
<b>8: Authorisation Date</b>	21/11/2023
<b>9: Annexes attached</b>	Annex 1 and/or Annex 2

### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

**SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED**, SCION HOUSE, STIRLING UNIVERSITY INNOVATION PARK, STIRLING,  
FK9 4NF, UNITED KINGDOM

Human Investigational Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1) IMPORTATION OF MEDICINAL PRODUCTS (according to part 2)
<b>Part 1 - MANUFACTURING OPERATIONS</b> <b>[ 1.1 ] Sterile Investigational Medicinal Products</b> [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) [ 1.1.1.2 ] Lyophilisates <b>Special Requirements</b> Cytotoxics

[ 1.1.1.4 ] Small volume liquids

**Special Requirements**

Cytotoxics

[ 1.1.1.6 ] Other aseptically prepared products

Suspensions

**Special Requirements**

Cytotoxics

**[ 1.2 ] Non-sterile investigational medicinal products**

[ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms)

[ 1.2.1.15 ] Other non-sterile medicinal products

Lyophilisation of non-sterile active ingredients / excipients for use as starting materials in solid oral dosage manufacturing elsewhere

**Special Requirements**

Cytotoxics

**[ 1.3 ] Biological investigational medicinal products**

[ 1.3.1 ] Biological medicinal products

[ 1.3.1.2 ] Immunological products

[ 1.3.1.4 ] Gene therapy products

[ 1.3.1.5 ] Biotechnology products

[ 1.3.1.8 ] Other biological medicinal products

Plasmid, DNA, RNA, peptides, proteins and antibodies products. This list is only indicative of the product handled.

**Special Requirements**

Cytotoxics

**[ 1.4 ] Other investigational medicinal products or manufacturing activity**

[ 1.4.2 ] Sterilisation of active substances/excipients/finished products:

[ 1.4.2.1 ] Filtration

**[ 1.5 ] Packaging**

[ 1.5.2 ] Secondary packaging

**Part 2 - IMPORTATION OF MEDICINAL PRODUCTS**

**[ 2.2 ] Batch certification of imported medicinal products**

[ 2.2.3 ] Biological medicinal products

[ 2.2.3.4 ] Gene therapy products

**[ 2.3 ] Other Importation Activities**

[ 2.3.1 ] Site of Physical Importation

[ 2.3.2 ] Importation of Intermediate which undergoes further processing